Raymond James cuts Alignment Healthcare stock price target on star rating downgrade
Raymond James cut its price target on Alignment Healthcare (ALHC) to $10 from $19, citing a star rating downgrade for its California plan. The firm estimates a $420M EBITDA headwind in 2028, though some may be mitigated. ALHC's stock is down 61.8% YTD, trading at $7.55. Multiple analysts downgraded the stock, but TD Cowen maintained a Buy rating.
How this was made
The 30-second read
Why it matters
The analyst actions drive a negative sentiment and could trigger short‑term selling pressure.
Market read
ALHC-specific analyst downgrade with potential spillover to peer health‑insurers.
What to watch
Potential mitigation from shared‑risk arrangements and benefit cuts could soften the EBITDA hit.
Background
Alignment Healthcare (ALHC) saw its largest California plan downgraded to 3.5 stars, prompting analyst target cuts and rating downgrades.
Ticker impact
Raymond James cut ALHC price target to $10 from $19 and downgraded rating after star rating downgrade, a fresh analyst action.
likely pressure as the market prices in the reduced target and rating downgrade
The downgrade is a new, material analyst action that directly affects valuation expectations.
Market effects
May weigh on other Medicare‑linked health insurers as rating pressures spread.
Limited to U.S. health‑insurance sector.
Low
Counterpoint
Some investors may see the price drop as a buying opportunity if the star rating issue resolves.
Key entities
- AnalystRaymond James
Lowered price target and rating for ALHC.
- AnalystBofA Securities
Downgraded ALHC to Neutral.
